Continuation or reintroduction of statin therapy after the first trimester in high-risk women with familial hypercholesterolemia appears safe without increased risk of congenital malformations (adjusted OR 1.03, 95% CI 0.89–1.18) and may reduce prolonged off-treatment LDL-C exposure associated with increased ASCVD risk.
This review provides practical guidance for managing lipid-lowering therapy in women with familial hypercholesterolemia during pregnancy and family planning to minimize prolonged off-statin periods and cumulative LDL-C exposure.
Effect estimate: Meta-analysis: adjusted OR 1.03 (95% CI 0.89–1.18) for congenital malformations with statin exposure in early pregnancy; Subgroup analysis OR 1.47 (95% CI 1.12–1.93) for congenital malformations with high-intensity statins (95% CI 0.89-1.18 for main result; 1.12-1.93 for high intensity subgroup)
Women with familial hypercholesterolaemia (FH) accrue a high lifetime LDL-cholesterol (LDL-C) burden and face excess atherosclerotic cardiovascular disease risk that is amplified by prolonged off-statin periods related to family planning, pregnancy and breastfeeding. Current practice and guidance are fragmented, and many women experience long-treatment interruptions that increase the cumulative LDL-C exposure. This review provides a contemporary account of the extant evidence and offers practical, evidence-informed recommendations that focus primarily on women with FH; we address contraception, preconception assessment, management during pregnancy, breastfeeding duration, and timely postpartum reintroduction of lipid-lowering therapy (LLT). We emphasize individualized shared decision-making and multidisciplinary care involving lipidologists, obstetricians, genetic counsellors and other specialists; we also consider alternative options to reduce the risk of prolonged off-treatment periods. Recent regulatory and guideline changes that allow more flexible consideration of statin use in pregnancy for selected high-risk women highlight the need for clear guidance to minimize the cumulative LDL-C exposure, while respecting maternal-fetal safety. Priority actions include development of explicit family-planning and pregnancy guidance for women with FH and implementation strategies to embed these practices into routine care.
Holven et al. (2026) conducted a review in Women with heterozygous familial hypercholesterolemia (HeFH) during reproductive period including pregnancy and breastfeeding. Statin therapy including continuation or reintroduction after first trimester during pregnancy in selected high-risk women with FH vs. Discontinuation of statin therapy during pregnancy was evaluated on Risk of congenital malformations and ASCVD risk related to statin exposure during pregnancy and cumulative LDL-cholesterol burden in women with FH (Meta-analysis: adjusted OR 1.03 (95% CI 0.89–1.18) for congenital malformations with statin exposure in early pregnancy; Subgroup analysis OR 1.47 (95% CI 1.12–1.93) for congenital malformations with high-intensity statins, 95% CI 0.89-1.18 for main result; 1.12-1.93 for high intensity subgroup). Continuation or reintroduction of statin therapy after the first trimester in high-risk women with familial hypercholesterolemia appears safe without increased risk of congenital malformations (adjusted OR 1.03, 95% CI 0.89–1.18) and may reduce prolonged off-treatment LDL-C exposure associated with increased ASCVD risk.